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AbstrAct:
Proteotoxic stress (PS) is generated in cells under a variety of conditions involving 
accumulation of misfolded proteins. To avoid the toxicity of unmitigated PS, cells 
activate the heat shock response (HSR). HSR involves upregulation of factors 
such as ubiquitin and the non-housekeeping chaperone Hsp70 which assist 
with metabolism of aberrant proteins. The PS-HSR axis is a potential anticancer 
treatment target since many tumor cells display constitutive PS and dependence 
on HSR due to their rapid rates of proliferation and translation. In fact, induction of 
PS via stimulation of protein misfolding (hyperthermia), inhibition of proteasomes 
(bortezomib) or inhibition of Hsp90 (geldanamycin) have all been considered 
or used for cancer treatment. We found that combination of bortezomib with an 
inducer of protein misfolding (hyperthermia or puromycin) resulted in enhanced 
PS. HSR was also induced, but could not mitigate the elevated PS and the cells 
died via largely p53-independent apoptosis. Thus, combination treatments were 
more cytotoxic in vitro than the component single treatments. Consistent with this, 
combination of non-toxic doses of puromycin with bortezomib significantly increased 
the antitumor activity of bortezomib in a mouse model of multiple myeloma. 
These results provide support for using combination treatments that disrupt the 
balance of PS and HSR to increase the therapeutic index of anticancer therapies.
IntroductIon
Proteotoxic stress (PS) is generated by accumulation 
of misfolded proteins in cells under a variety of conditions 
including hyperthermia, hypoxia, and exposure to 
denaturing agents or drugs that inhibit proteasome or 
chaperone activities [1-3]. PS can be toxic if misfolded 
proteins accumulate and aggregate in the cells. To avoid 
the toxicity of PS, cells activate an adaptive response, 
known as the heat shock response (HSR)[4]. 
The adaptive HSR involves induction of factors and 
pathways that serve to mitigate the burden of misfolded 
proteins. Thus, additional chaperones (e.g., Hsp70) are 
synthesized to assist in metabolism of misfolded proteins, 
ubiquitin is upregulated to allow for more proteasome-
mediated degradation, and general translation is 
attenuated [5,6]. In mammalian cells, the adaptive HSR 
depends upon activation of the transcription factor HSF1 
[7]. HSF1 is required for expression of the inducible form 
of Hsp70 as well as other chaperones and some stress-
related transcription factors [1].
Many tumors and tumor-derived cells contain 
elevated levels of misfolded proteins due to the high 
level of translation associated with their rapid rate of 
proliferation, as well as specific intracellular conditions, 
such as glycolysis-related acidification [8,9]. Therefore, Oncotarget 2011; 2:  209 - 221 210 www.impactjournals.com/oncotarget
these tumor cells exist under conditions of constant PS 
and exhibit constitutive activation of HSR. The elevated 
expression in tumors of both “housekeeping” heat shock 
proteins  (HSP)  such  as  the  chaperone  Hsp90  and  the 
inducible form of Hsp70 is a reflection of their level of PS. 
Thus, the ability to properly respond to PS is especially 
important for survival of tumor cells. This is illustrated by 
the finding that genetic or pharmacological inhibition of 
Hsp70 synthesis in response to PS in tumor cells increased 
the toxicity of PS and resulted in apoptosis [10-12]. In 
addition, HSF1 knock-out mice showed reduced frequency 
of tumor formation in response to oncogene expression 
or exposure to oncogenic chemicals as compared to wild 
type mice [13-14]. Thus, HSF1-related gene expression 
represents a principal mechanism by which cancer cells 
survive in the face of constant PS.
Since tumor cells are particularly prone to PS and, 
thereby, dependent upon effective HSR, targeting of HSR 
has been recognized as an attractive strategy for anti-
cancer therapy. Previous studies have demonstrated that 
it is possible to manipulate the toxicity of PS induced 
by different stimuli, such as hyperthermia, proteasome 
inhibitors and chaperone inhibitors to achieve greater 
tumor cell killing. One way to increase the toxicity of 
PS is to suppress the adaptive HSR by blocking Hsp70 
synthesis. For example, we showed that the anti-malaria 
drug quinacrine and its close analogue 9-amino-acridine 
prevented PS-specific induction of Hsp70 and increased 
the toxicity of PS for both tumor cells in vitro and tumors 
in vivo [12]. Other studies demonstrated increased 
cytotoxicity through combination of the Hsp90 inhibitor 
geldanamycin with cisplatin (an inhibitor of HSF1 DNA 
binding) [15] or combination of hyperthermia with 
siRNA-mediated knockdown of Hsp70 [10]. In these 
three  studies,  the  first  component  of  the  combination 
treatment is a PS inducer, while the latter component acts 
as an inhibitor of HSR.
We proposed an alternative approach for increasing 
the toxicity of PS in tumor cells based on the idea that the 
HSR capacity of a cell is limited by the expression levels 
of a small number of genes (e.g., those encoding inducible 
chaperones, such as Hsp70 [3,7], and ubiquitin [16]). The 
roles of chaperones and ubiquitin in protein metabolism 
that lead to effective HSR require that they are available in 
sufficient amounts to interact with most of the misfolded 
protein molecules present in the cell [2]. Thus, although 
HSR is highly inducible by PS and typically very effective, 
we hypothesized that it might be possible to increase the 
level of misfolded proteins such that it cannot be matched 
by the cell’s HSR (capacity to synthesize chaperones and 
ubiquitin). Such “enhanced proteotoxic stress” (EPS) 
would be expected to be highly cytotoxic, especially 
for tumor cells which are constitutively coping with 
pre-existing PS. In this study, we show that EPS can be 
generated through combination of a treatment that causes 
misfolding of proteins (hyperthermia or puromycin) with 
Figure 1: combined treatment with hyperthermia and 
bortezomib produces enhanced proteotoxic stress (EPs). 
A. Northern blot analysis of HT1080 cells left untreated (contr) or 
treated with 100nM bortezomib for 5 h (BZ), hyperthermia (heat 
shock at 430C for 1 h, HS), or hyperthermia together with 100nM 
bortezomib (HS/BZ). For the combined treatment, bortezomib was 
added just before heat shock (430C for 1 h), after which the cells were 
transferred to 370C and incubated for an additional 4 h. 10µg of total 
RNA from each sample was analyzed by Northern hybridization with 
the Hsp70A1probe and the GAPDH probe (as a loading control).
b. Western blot analysis of protein extracts (10µg) from HT1080 
cells treated as described in panel A. Blots were probed with anti-
Hsp70 antibody and anti-tubulin antibody (tub) as a loading control. 
c. Total protein ubiquitination in HT1080 cells treated as described 
in panel A. Western blotting was performed using 10 µg of protein 
extract. Blots were probed with anti-ubiquitin antibody (top panel) 
and anti-tubulin antibody (bottom panel, tub) as a protein loading 
control.
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the proteasome inhibitor bortezomib. We demonstrate 
that simultaneous induction of protein misfolding and 
inhibition of proteasome-mediated degradation induces 
EPS in several different types of tumor cells and leads 
to cell death in vitro and suppression of tumor growth in 
vivo. The tested drug combinations show greater efficacy 
than either single component treatment, both in inducing 
PS (generating EPS) and in killing tumor cells in vitro and 
in vivo. These results indicate that such combinatorial PS-
targeting therapies hold substantial promise as improved 
cancer treatments.
rEsuLts
Induction of EPs by a combination of 
hyperthermia and bortezomib
The objective of this study was to test whether we 
could create EPS that would be cytotoxic in tumor cells 
without direct inhibition of HSR. We hypothesized that the 
severity of PS would be enhanced by combining a treatment 
that induces protein misfolding, such as hyperthermia [17], 
with a treatment that prevents degradation of misfolded 
proteins, such as the proteasome inhibitor bortezomib 
[3]. Using inducible Hsp70 expression as a marker of 
PS, we found that combined treatment with hyperthermia 
and bortezomib resulted in a much higher level of PS 
than either agent alone (Fig. 1A, B). As expected based 
on the well-established relationship between Hsp70 
expression and PS, we also observed much higher levels 
of ubiquitinated proteins (presumably misfolded) in cells 
treated with hyperthermia and bortezomib than in cells 
treated with either agent alone (Fig. 1C). These data 
indicate that combined treatment with hyperthermia and 
bortezomib produces EPS. 
The EPS generated by hyperthermia+bortezomib 
was not effectively mitigated by coincident induction 
of HSR in co-treated cells, as illustrated by aggregation 
of misfolded proteins in the cells (Fig. 2). Heat shock 
treatment (1 hour at 43oC) of H1299 cells carrying an 
HSF1-regulated GFP expression construct (H1299-HSE/
GFP) resulted in a high level of GFP expression which 
was still evident 36 hours later (Fig. 2B). By 72 hours 
after heat shock, most of the GFP protein was degraded 
in cells that did not receive any further treatment (Fig. 
2C, 2Ca), indicating effective HSR. In contrast, if the 
heat-shocked  H1299-HSE/GFP  cells  were  incubated 
in the presence of bortezomib for the subsequent 72 
hours, GFP accumulated in aggresomes (Fig. 2D, 2Da). 
These data suggest that the combination of an inducer of 
protein misfolding (hyperthermia) with an inhibitor of 
proteasomal degradation (bortezomib) produces a level 
of PS that the cell cannot mitigate, even though HSR is 
induced by the treatments as well.
We next determined whether EPS generated by 
treatment with hyperthermia+bortezomib resulted in 
enhanced cytotoxicity. Under conditions of standard PS, 
such as that generated by bortezomib or hyperthermia 
alone, the induced adaptive HSR is usually sufficient to 
allow cell survival. For example, HT1080, HCT116 (data 
not shown) and HeLa (Fig. 3A, B) cells can completely 
recover from 1 hour incubation at 430C during additional 
incubation at 37oC. Treatment with 40 nM of bortezomib 
for 18 hours induces a similar level of PS (data not shown), 
but was slightly more toxic to HeLa cells than hyperthermia 
(Fig. 3A, B). This is likely due to the fact that proteasome 
inhibition has other effects in addition to induction of 
PS, such as causing accumulation of the pro-apoptotic 
Figure 2: Accumulation of heat shock-induced GFP in aggresomes in bortezomib treated cells. H1299-HSE/GFP cells were 
left untreated (contr) or treated with hyperthermia (HS) at 430C for 1 h to induce HSF1-dependent GFP synthesis. After heat shock, the cells 
were transferred to 370C and incubated for the indicated amounts of time (36 or 72 h) with or without 40nM bortezomib (BZ).  The synthesis 
(HS36h), degradation (HS72h), and accumulation in aggresomes (HS/BZ72h) of GFP were monitored by fluorescent microscopy. 
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factor p53 and suppressing the pro-survival activities of 
NF-kappaB and Akt [18.19]. Nevertheless, both of the 
above-described PS-inducing treatments (heat shock and 
bortezomib) leave the majority of treated cells alive. In 
contrast, we found that combination of the two treatments 
resulted in a much higher level of cell death (Fig. 3A, B). 
Analysis of PARP cleavage demonstrated that cell death 
induced by hyperthermia+bortezomib is accompanied by 
activation of caspases indicative of apoptosis (Fig. 3C). 
These data demonstrate that the extent of cell death in cells 
treated with hyperthermia+bortezomib correlated with 
the increased level of PS generated by the combination 
treatment (Fig. 1). This supports our hypothesis that 
the cytotoxity of the combination treatment is due to 
accumulation of misfolded proteins to a level that exceeds 
the capacity of the cell’s natural adaptive HSR.
Induction of EPs by a combination of puromycin 
and bortezomib 
Like hyperthermia, some pharmacological agents 
also induce proteins’ misfolding. For example, the 
antibiotic puromycin, which acts as a non-functional 
analogue of aminoacyl tRNA, causes premature 
termination of translation and accumulation of aborted, 
improperly folded translation products [20]. We therefore 
hypothesized that puromycin, similar to hyperthermia, 
would enhance the antitumor effect of bortezomib. As 
shown in Figure 4, treatment of HT1080 tumor cells in 
vitro with a combination of puromycin and bortezomib 
caused greater PS and adaptive HSR than treatment with 
either drug alone. The classic marker of adaptive HSR, 
Hsp70, was upregulated to a greater extent at both the 
protein (Fig. 4A) and mRNA (Fig. 4B) levels by the drug 
combination as compared to either single drug. Notably, 
induction of HSR (as judged by induction of Hsp70 
expression) by puromycin was observed at a concentration 
that does not cause suppression of general translation 
(Fig. 4A). Similar effects of bortezomib, puromycin and 
their combination on induction of HSR were observed in 
HeLa cells carrying an Hsp70-regulated GFP expression 
constructed (HSE/GFP) (Fig. 5A). Consistent with the 
effects of puromycin+bortezomib on Hsp70, we found that 
the combination treatment also led to greater accumulation 
of ubiquitinated proteins in HT1080 cells as compared to 
treatment with either drug alone (Fig. 4C). Taken together, 
these results indicate that combination of bortezomib with 
puromycin (as with hyperthermia) generates EPS within 
the treated cells.
Generation of EPS by combined 
puromycin+bortezomib treatment correlated with 
synergistic cytotoxicity of the two drugs. Treatment of 
HeLa HSE/GFP cells with 400 ng/ml puromycin and 40 nM 
bortezomib for 18 hours resulted in significantly reduced 
cell viability as compared to treatment with either drug 
alone using the same dose/time (Fig. 5A, B). The observed 
Figure 3: EPs generated by combined hyperthermia and 
bortezomib is more cytotoxic than either treatment alone. 
A.  combination of hyperthermia and bortezomib is toxic to 
HeLa cells. HeLa cells were left untreated (Contr) or treated with 
hyperthermia (430C heat shock for 1h) (HS), 40 nM bortezomib for 
18h (BZ), or their combination (HS/BZ).
b. Methylene-blue-based quantitation of the results of the cell survival 
assay presented in panel A.
c.  combination of hyperthermia and bortezomib induces 
apoptosis in HeLa cells. Total protein extracts from HeLa cells 
treated as described in (A) were analyzed by Western blotting with 
anti-PARP, anti-Hsp70, and anti-tubulin (tub, control for protein 
loading)  antibodies.  Full-length  PARP  and  the  apoptosis-specific 
cleaved PARP fragment (PARP cl.) are indicated. Hsp70 was assessed 
as a marker of adaptive HSR.
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reduction in cell viability correlated with appearance of 
morphological (small, rounded, detached cells (Fig.5A)) 
and biochemical (Fig. 5C) signs of apoptosis. These 
data support our hypothesis that combination treatments 
resulting in accumulation of misfolded proteins to levels 
that exceed the salvaging capacity of HSR will lead to cell 
death and demonstrate that such death proceeds, at least in 
part, via apoptosis.
Involvement of p53 in the response of cells to EPs
Inhibition of proteasome activity results in 
stabilization and accumulation of the key pro-apoptotic 
protein p53 [21]. To examine the involvement of p53 in 
EPS-induced cytotoxicity, we used isogenic p53-/- and 
p53 wild type HCT116 cell lines [22] and compared the 
effects of nutlin-3a, an MDM2 inhibitor that specifically 
prevents p53 degradation [23,24], with those of 
bortezomib. Both nutlin-3a and bortezomib stabilize p53 
presumably by preventing its degradation by proteasomes 
[24,25]; however, only bortezomib also induced PS/HSR. 
These effects are illustrated in Figure 6A for HCT116 cells 
with wild type p53, using Hsp70 as a marker of PS/HSR. 
Under the conditions used in this experiment, stabilization 
of p53 by nutlin-3a was not sufficient to induce apoptosis. 
This was illustrated by a lack of PARP cleavage (Fig. 
6A) and no change in cell survival (Fig. 6B). In contrast, 
bortezomib treatment (50 nM for 24 hours) producing 
the same level of p53 stabilization caused substantial 
apoptosis of p53 wild type cells (as indicated by PARP 
cleavage and cell survival assays). These results indicate 
that the toxicity of bortezomib is not due to stabilization 
of p53, but is correlated with induction of PS. Analysis 
of p53-/- HCT116 cells provided additional support for 
this conclusion. Thus, even in the complete absence 
of p53, bortezomib (but not nutlin-3a) induced both 
Hsp70 expression indicative of PS/HSR and noticeable 
PARP cleavage indicative of apoptosis (Fig. 6A). The 
cytotoxicity of bortezomib, but not nutlin-3a, towards 
p53-/- cells was also evident in cell survival assays (Fig. 
6B).
The experiments described above (Fig. 6A, B) 
demonstrate that the accumulation of p53 induced by 
nutlin-3a is not sufficient on its own to trigger apoptosis in 
HCT116 cells and that p53 is not required for PS-induced 
cytotoxicity. Nevertheless, p53 activity might play a role 
in the efficiency of apoptosis induced by PS or EPS. This 
possibility is supported by the greater level of PARP 
cleavage and cell death seen in bortezomib-treated p53 
wild type HCT116 cells as compared to similarly treated 
p53-/- HCT116 cells (Fig. 6A, B) To further evaluate 
the role of p53 in the toxicity of PS, we treated p53 wild 
type and p53-/- HCT116 cells with 50 nM bortezomib, 
400 ng/ml puromycin or their combination for 24 hours 
and evaluated induction of PS/HSR (by Hsp70 expression 
assay) and apoptosis (by PARP cleavage and cell survival 
Figure 4: combined treatment with bortezomib and 
puromycin produces enhanced proteotoxic stress conditions 
(EPs).  A. Puromycin induces Ps and does not affect protein 
synthesis. HT1080 cells were treated for 4 h with puromycin (1 µM) 
(PM), bortezomib 100 nM (BZ), or their combination (PM/BZ), and 
then labeled with S
35
–methionine for 60 min. S
35
-labeled proteins from 
HT1080  cells  were  analyzed  by  SDS-PAGE  and  autoradiography. 
Protein extracts from equal numbers of cells were loaded on the gel. 
The position of Hsp70 (an indicator of PS) is marked by the arrow. 
b. combined treatment with bortezomib and puromycin induces 
EPs. Northern blot analysis was performed using RNA from HT1080 
cells treated for 18 h with 40 nM bortezomib (BZ), 400 nM puromycin 
(PM), or their combination (BZ/PM). Blots were hybridized with 
probes for Hsp70 (top panel) and GAPDH (RNA loading control, 
bottom panel). c. total protein ubiquitination in response to 
bortezomib, puromycin and their combination. Western blotting 
was performed using 10 µg of total protein extract from HT1080 cells 
treated as described in (b). Blots were probed with anti-ubiquitin 
antibody (top panel) and anti-tubulin antibody (bottom panel, tub) as 
a protein loading control.
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assays). 
In both cell lines, treatment with either 50 nM 
bortezomib or 400 ng/ml puromycin resulted in PS and 
treatment with their combination produced EPS (as 
evidenced by the level of Hsp70 induction, Fig.6C). 
PS resulting from treatment with puromycin alone was 
a weak inducer of apoptosis in p53 wild type and p53-
/- HCT116 cells (illustrated by the low level of PARP 
cleavage (Fig. 6C) and cell death (Fig. 6D)). In contrast, 
while PS following from treatment with bortezomib alone 
did lead to noticeable apoptosis in p53-/- HCT116 cells, 
the extent of apoptosis was greater in similarly treated p53 
wild type cells (Fig. 6C, D). These data are consistent with 
those shown in Figure 6B for similar treatment of p53-
positive and –negative HCT116 cells with bortezomib 
alone. The extent of apoptosis induced by treatment of 
p53-/- cells with bortezomib alone was not substantially 
enhanced even when the dose of drug was doubled to 100 
nM (Fig. 6D). 
Unlike treatment with either drug alone, combined 
treatment with puromycin+bortezomib resulted in 
substantial apoptosis in p53 wild type and p53-/- HCT116 
cells. The extent of apoptosis in combination-treated p53-
/- cells was not dependent upon bortezomib dose (50 
nM versus 100 nM). Even in p53 wild type cells, which 
showed an apoptotic response to bortezomib alone, the 
response was stronger following combination treatment. 
As for treatment with bortezomib alone, the extent of 
apoptosis induced by bortezomib+puromycin was greater 
in the p53 wild type cells than in the p53-/- cells. Taken 
together, the data shown in Fig. 6A-D indicate that PS/
EPS-induced apoptosis is largely p53-independent: p53 
activity is not required for PS/EPS-induced apoptosis; 
however, it does appear to contribute to the extent of the 
observed apoptosis. 
Anti-tumor efficacy of PSTT in a mouse model of 
multiple myeloma
Although bortezomib is FDA-approved for treatment 
of multiple myeloma, its clinical use is complicated by 
high general toxicity [26,27]. Based upon our in vitro 
data showing that combining puromycin with bortezomib 
increased tumor cell killing (see above), we hypothesized 
that combined administration of puromycin with 
bortezomib in vivo would allow an anti-tumor therapeutic 
effect to be reached at lower doses of bortezomib, thereby 
reducing general toxicity. To test this possibility, we used 
a model consisting of MPC11 mouse multiple myeloma 
cells grown as syngeneic tumors in Balb/c mice. Before 
performing the in vivo study, we tested the effect of 
different concentrations of bortezomib (1, 1.5, 2, 3 or 5 
nM) alone or in combination with different concentrations 
of puromycin (200 or 400 ng/ml) on survival of MPC11 
cells growing in culture (Fig. 7A). As expected, increasing 
concentrations of bortezomib resulted in increased cell 
death. In the middle part of the dose-response curve 
(1.5 and 2 nM bortezomib), increased cytotoxicity was 
Figure 5: combined treatment with bortezomib+puromycin is more cytotoxic than treatment with either drug alone.  A.  
toxic effect of EPs induced by combination of bortezomib and puromycin.  GFP expression in HeLa-HSE/GFP cells treated with 40 nM 
bortezomib (BZ), 400 nM puromycin (PM), or their combination (BZ/PM) for 18h. Toxicity is indicated by changes in the cells’ morphology 
and their detachment from the plate. b. Cell survival assay with HeLa-HSE/GFP cells treated as described in (A). Methylene blue was used for 
quantitation. c. Apoptosis is induced in Ht1080 cells in response to EPs. Total protein extracts from HT1080 cells treated with bortezomib 
(BZ), puromycin (PM), hyperthermia (HS.), and their combinations as described in (A) and in the legend to Figure 3 were analyzed by Western 
blotting with anti-PARP antibody. Full-length PARP and the apoptosis-specific cleaved PARP fragment (PARP/cl) are indicated by arrows. 
Equivalent amounts of protein were loaded in all lanes.  
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observed with inclusion of puromycin in the cell treatment. 
This effect of puromycin was also dose-dependent, being 
stronger with 400nM than with 200nM puromycin. These 
data indicate that, as for HeLa and HT1080 cells (see 
above), combination of puromycin and bortezomib results 
in enhanced death of MPC11 mouse MM cells. 
We next evaluated whether combination of puromycin 
and bortezomib would also lead to killing of MPC11 cells 
growing as solid tumors in mice. Four groups of BALB/c 
mice (5 animals/group) were injected sub-cutaneously on 
both sides of their bellies with 2x105 MPC11 cells. Mice 
were  given  their  first  drug  injection  (intraperitonealy) 
when at least one tumor reached 50 mm3 in size. Groups 
were injected with PBS (negative control), 0.5 mg/kg 
bortezomib alone, 5 mg/kg puromycin alone, or 0.5 mg/
kg bortezomib + 5 mg/kg puromycin. We chose to use the 
0.5 mg/kg dose of bortezomib since the reported effective 
antitumor dose of bortezomib (1 mg/kg dose [28]) caused 
significant general toxicity as indicated by mouse weight 
loss (Fig. 7B) and combination of 1 mg/kg bortezomib 
with 5 mg/kg puromycin had the same anti-tumor effect 
and same toxicity as 1 mg/kg bortezomib used alone (data 
not shown). Reduction of the bortezomib dose to 0.5 mg/
kg resulted in much lower general toxicity, but also led 
to a significant decrease in its anti-tumor effect (Fig. 7B 
and data not shown). Importantly, however, when this 
lower dose of bortezomib (0.5 mg/kg) was combined with 
5 mg/kg puromycin (itself non-toxic and ineffective as a 
single agent), inhibition of tumor growth was enhanced 
without a substantial increase in general toxicity (Fig. 7B, 
C). The tested combination of 0.5 mg/kg bortezomib + 5 
mg/kg puromycin was as effective in suppressing tumor 
growth as the therapeutically optimal bortezomib dose 
(1.0 mg/kg) while showing less severe toxicity, as judged 
by mouse body weight loss (Fig.7B, C, data not shown). 
dIscussIon
The maintenance of protein homeostasis in cells 
requires  the  activities  of  chaperones,  such  as  Hsp90, 
Hsp70, and Hsp27, and the ubiquitin-proteasome system 
[29],  which  together  serve  to  inactivate  and  degrade 
misfolded proteins. Elevation of the intracellular 
concentration of misfolded proteins can result from 
hyperthermia (heat shock), increased translation, exposure 
to protein-denaturing agents, or treatment with agents that 
interfere with natural mechanisms of misfolded protein 
processing,  such  as  the  Hsp90  inhibitor  geldanamycin 
Figure 6: role of p53 in cytoxicity induced by Ps and EPs.  A. stabilization of p53 by nutlin-3a is not toxic for wt Hct116 cells 
and p53 is not required for Ps-induced toxicity. P53 wild type (wt) and p53-/- HCT116 (p53-/-) cells were left untreated (contr) or treated 
with nutlin-3a (NT, 100 µM) or bortezomib (50 nM, BZ50) for 24 h. Total protein extracts (10 µg) were analyzed by Western blotting with anti-
PARP (top panel), anti-Hsp70 (middle panel) and anti-p53 (bottom panel) antibodies. The anti-PARP antibody detects both full-length PARP 
and the apoptosis-specific cleaved fragment (PARP/cl). b. Methylene blue-based quantitation of cell survival assay for the cells described in 
(A). c. the extent of Ps/EPs-induced apoptosis is greater in wild type cells than in p53-/- cells. P53 wild type HCT116 cells (wt) and 
HCT116p53-/- cells (p53-/-) were left untreated (contr) or treated with bortezomib (BZ, 50 or 100 nM), puromycin (PM, 400 ng/ml) or their 
combination as indicated below each lane for 24 h. Western blotting was performed as described for (A). Equivalent amounts of protein were 
loaded in all lines. d. Methylene blue-based quantitation of cell survival assay for the cells described in(c). Results are the average of two 
experiments as described in Materials and Methods.
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Figure 7:  Effect of EPs on MPc-11 multiple myeloma tumor growth. A. combinatorial toxicity of bortezomib and puromycin 
on MPc-11 multiple myeloma cells in vitro. MPC-11 cells growing in culture were treated with the indicated amounts (x-axis) of bortezomib 
alone or in combination with 200 nM or 400 nM puromycin for 18 h. Cell survival was estimated by counting trypan blue-excluding cells. 
The data shown represent the average of two independent experiments. b. In vivo drug toxicity. General toxicity of treatment regimens was 
evaluated by daily measurement of mouse body weight. Groups of 3 BALB/c mice were injected with the indicated doses of drugs on the days 
marked by arrows. Each data point represents the average weight in the group relative to the average weight in the group before first drug 
injection.  c. Effect of combined bortezomib + puromycin treatment on MPc-11 multiple myeloma tumor growth in vivo. Groups of 
5 BALB/c mice carrying syngeneic transplanted MPC-11-derived tumors (see Materials and Methods) were injected (i.p.) with PBS (contr), 
0.5 mg/kg bortezomib (BZ0.5), 5 mg/kg puromycin (PM5), or 0.5 mg/kg bortezomib + 5 mg/kg puromycin (BZ0.5/PM5) on the days marked 
with arrows. Tumors were measured daily. The graph shows the average relative tumor growth within each treatment group (relative tumor 
growth=tumor volume on day of measurement (V) divided by tumor volume of the day of the first drug injection (Vor). Error bars indicate 
standard deviation. Animals were sacrificed if their tumors reached 1200 mm3 in volume. 
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or the proteasome inhibitor bortezomib [15,30-32]. 
Regardless of the underlying cause, accumulation of 
misfolded proteins leads to PS, which, if not mitigated, 
can lead to protein aggregation and cell death, often via 
apoptosis [33,34]. Cells are typically able to survive PS, 
though, due to activation of the adaptive HSR, which 
involves induction of HSF1-mediated transcription of 
genes encoding additional chaperones, such as Hsp70, 
and other stress-related proteins [2,31]. 
Effective HSR is particularly important for survival 
of cancer cells, which are characterized by constitutively 
high levels of PS and coincident dependence on HSF1 
activity [13,35]. This presents the attractive possibility 
of targeting PS and HSR as anti-cancer therapies and 
indeed, inducers of PS, such as chaperone inhibitors 
and proteasome inhibitors (e.g., bortezomib) have 
been introduced as such. It is likely, however, that the 
effectiveness of these drugs is limited by the cell’s 
natural HSR. Therefore, strategies aimed at increasing the 
toxicity of PS towards tumor cells, such as suppression 
of HSR, have been explored [10,12,13,15]. For example, 
in our previous publication, we described the ability of 
the anti-malaria drug quinacrine to block expression of 
Hsp70 in response to PS [12]. Due to its effect on Hsp70, 
combination of quinacrine with inducers of PS, such as 
hyperthermia, bortezomib, or geldanamycin resulted in 
increased cytotoxicity in vitro and increased suppression 
of tumor growth in vivo in syngeneic transplant mouse 
models [12]. These findings, together with those from a 
number of other studies, demonstrate that suppression of 
HSR under conditions of PS increases the toxicity of PS, 
induces cancer cell death, and affects tumor growth [13]. 
In the current study, we tested an alternative approach 
to increasing the anti-tumor toxicity of PS inducers. 
Rather than blocking HSR in response to a given level 
of PS, this alternative approach leaves HSR unchanged 
while increasing the level of PS. We hypothesized that 
combining PS inducers with different target pathways (e.g., 
combining a treatment that causes misfolding of proteins 
with a treatment that prevents their degradation) would 
create EPS that would exceed the capacities of the cell’s 
adaptive HSR and prove intolerable for cell survival. Such 
a strategy might be expected to be particularly effective 
for killing of tumor cells since their HSR capacity is 
partially exhausted due to pre-existing PS.
Our results demonstrate that combined treatment 
with the proteasome inhibitor, bortezomib, and an inducer 
of protein misfolding (either hyperthermia or puromycin) 
produced EPS and that EPS correlated with cytotoxicity. 
Thus, in several cell lines in vitro, both combination 
treatments greatly increased the level of PS (as evidenced 
by the level of Hsp70 expression and accumulation of 
ubiquitinated proteins) over that induced by either single 
component of the treatment used alone. Similarly, for both 
hyperthermia+bortezomib and puromycin+bortezomib, 
the combination treatment was much more cytotoxic than 
single treatments. The enhanced cell killing achieved with 
the combination treatments does not rely on induction 
of any toxic process other than the accumulation of 
misfolded proteins caused by bortezomib alone, but 
simply increases formation of misfolded proteins such 
that the PS is “enhanced.”
Proteasome inhibition leads to stabilization and 
accumulation of p53, a major pro-apoptotic regulator 
of  cell  death/survival  [36-38]. This  plays  an  important 
role  in  the  anti-tumor  efficacy  of  bortezomib  [25,39]. 
Accordingly, the resistance of some tumors to proteasome 
inhibitors has been attributed to their p53-negative 
status or failure of the proteasome inhibitor to stabilize 
p53 [40-42]. Moreover, the expression of wild type p53 
in B lymphomas made them sensitive to bortezomib in 
vitro and in vivo [35].In other studies, however, the 
accumulation of p53 and the expression of wild type p53 
in p53-/- tumor cells did not change the sensitivity of cells 
to apoptosis induced by proteasome inhibitors [43,44]. We 
found that combination treatments that produced EPS in 
cultured tumor cells also reduced cell survival and induced 
PARP cleavage, indicative of apoptosis. Given the known 
effects of bortezomib on p53, we performed experiments 
to evaluate the role of p53 in EPS-induced cell death. 
Use of nutlin-3a, a compound that specifically stabilizes 
p53 without inducing by PS, showed that stabilization 
of p53 is not, in itself, sufficient to trigger apoptosis in 
HCT116 cells. Comparison of p53 wild type and p53-
/- HCT116 cells treated with bortezomib, puromycin, or 
their combination revealed that: (i) p53 is not absolutely 
required for induction of apoptosis by PS or EPS; and (ii) 
p53 does, nevertheless, contribute to the extent of PS/
EPS-induced apoptosis. The first conclusion ((i) above) 
was drawn from our data showing that treatment with 
bortezomib alone, and to a much greater extent, with 
bortezomib+puromycin, resulted in cleavage of PARP and 
reduction of cell survival in p53-deficient, as well as p53 
wild type, HCT116 cells. Despite the accepted involvement 
of p53 in the mechanism of action of bortezomib [25], 
there are previous publications that describe killing of 
p53-/- cells by proteasome inhibitors [43-45] which 
support our finding that PS/EPS-induced apoptosis is, at 
least in part, p53-independent. The second conclusion ((ii) 
above) is supported by our finding that p53-/- cells were 
less sensitive to bortezomib or bortezomib+puromycin 
than p53 wild type cells were. Thus, PARP cleavage and 
cell death were observed in p53-deficient cells exposed 
to PS- or EPS-inducing treatments, but were observed at 
higher levels in similarly treated p53 wild type cells. Our 
findings that EPS is more cytotoxic than PS and that EPS-
induced apoptosis is at least partially p53-independent 
suggest that EPS may be a promising treatment for 
p53-negative tumors in vivo. The enhanced cytotoxicity 
afforded by puromycin+bortezomib treatment might be 
particularly important in vivo since the time of bortezomib 
activity is limited in vivo by its detoxification in the liver Oncotarget 2011; 2:  209 - 221 218 www.impactjournals.com/oncotarget
by oxidative deboronation [46].
Bortezomib is an FDA-approved drug for treatment 
of multiple myeloma. Although multiple myeloma cells 
are highly sensitive to bortezomib in vitro and die within 
18 hours of exposure to just 5nM bortezomib, multiple 
myeloma tumors growing in mice are rather resistant to 
bortezomib treatment. In syngeneic and xenograft mouse 
multiple myeloma models, non toxic doses of bortezomib 
did not completely eliminate tumors, but only delayed their 
growth [28,47]. Bortezomib has shown efficacy in human 
multiple myeloma patients [48]; however, its application 
is  limited  by  induction  of  non-tumor-specific  toxicity. 
The typical dose of bortezomib used in the clinic is 1-1.3 
mg/m2. The drug is administered 4 times with 3 days 
intervals during the twice weekly treatment’s cycle [38] 
or 4 times up to 1.6 mg/m2 during the weekly treatment 
cycle [49]. The most frequent complication of bortezomib 
treatment is development of peripheral neuropathy, which 
is detected in 40-64% of treated patients with 14-30% 
requiring reduction of the drug dose or discontinuation of 
treatment [50,51]. 
Our  findings  in  cultured  cells  demonstrated  that 
tumor cell killing could be increased by combining 
bortezomib with puromycin. Therefore, we analyzed the 
effect of bortezomib+puromycin combination treatment 
as compared to single agent treatment on growth of 
MPC11 MM syngeneic tumor transplants in BALB/c 
mice. Under the treatment regimens used, high dose (1 
mg/kg) bortezomib significantly delayed tumor growth, 
but also caused substantial general toxicity (as evidenced 
by mouse weight loss). 5 mg/kg puromycin was non-
toxic and did not have any effect on tumor growth when 
administered alone and did not increase the anti-tumor 
toxicity of 1 mg/kg bortezomib treatment (data not 
shown). However, with a lower dose of bortezomib (0.5 
mg/kg) that showed low general toxicity, co-treatment 
with  5  mg/kg  puromycin  significantly  reduced  tumor 
growth as compared to low dose bortezomib alone. This 
combination of drugs produced low general toxicity. The 
ability to achieve tumor suppression with a reduced dose 
of bortezomib through its combination with puromycin 
is an attractive approach for anti-cancer therapy since it 
allows targeting of PS without the general toxicity that 
is associated with high doses of bortezomib. Overall, our 
data support the anti-cancer therapeutic potential of PSTT 
involving combinations of proteasome inhibitors and other 
drugs that target the PS-HSR axis, such as puromycin or 
quinacrine [12].
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Experiments with mice were conducted strictly in 
accordance with the protocol approved by the Roswell 
Park Cancer Institute IACUC. 
cell culture, lentiviral vectors, and drugs
HT1080,  HeLa,  H1299,  and  HCT116  cells 
were  cultured  in  Dulbecco  modified  Eagle’s  medium 
(Invitrogen/Gibco BRL, Carlsbad, CA) supplemented 
with 10% fetal calf serum. MPC11 cells were grown 
in complete RPMI-1640 medium supplemented with 
10% fetal calf serum, 2 mM L-glutamine, 100 g/ml 
streptomycin, 100 U/ml penicillin, 50 µg/ml Gentamicin 
(Life Technologies, Grand Island, NY). The construct 
for  HSF1-specific  EGFP  expression  (“HSE-GFP”)  was 
generated by inserting 6 copies of an HSF1 regulatory 
element (HSE; 5’-CAGAACGTTCTAG-3’) [52] upstream 
of the minimal CMV promoter in the PTR-mCMV-EGFP 
lentiviral vector (Cellecta, Inc. Mountain View, CA). 
Cells were infected with the resulting lentivirus at an MOI 
of 10 in the presence of 4 µg/ml polybrene overnight. The 
efficiency  of  infection  was  determined  by  detection  of 
EGFP expression in response to heat shock (incubation 
at 430C for 1h) using fluorescent microscopy. Between 70 
and 90% of the cells were infected by virus and expressed 
GFP in response to heat shock. Bortezomib was from 
LC Laboratories (Woburn, MA). The drugs puromycin, 
emetine, and nutlin-3a were from Sigma-Aldrich (St. 
Luis, MO). 
Western immunoblotting
Total protein extracts from cells were prepared in 
RIPA buffer (150 mM NaCl, 1% SDS, 10 mM Tris (pH 
8.0), 1% sodium deoxycholate, 1% NP-40) containing a 
protease inhibitor cocktail (Sigma, St. Louis, MO). 10 µg 
of the protein extracts were separated by electrophoresis 
in 4-20% gradient polyacrylamide gels with SDS and 
then transferred to nylon PVDF membranes (Amersham, 
Piscataway, NJ). Membranes were pre-incubated 
overnight in 5% milk solution, and then incubated for 1 
h in 1% milk solution with primary antibodies at 1:1000 
dilutions. The following primary antibodies were used: 
rabbit anti-Hsp70A1 inducible form (Assay Designs/
StressGen, Victoria, BC, Canada) and rabbit anti-ubiquitin 
(Santa Cruz Biotechnology, Santa Cruz, CA). Rabbit anti-
tubulin antibody was used to control for protein loading 
(Santa Cruz Biotechnology, Santa Cruz, CA). Apoptosis 
was analyzed by detection of caspase-specific cleavage Oncotarget 2011; 2:  209 - 221 219 www.impactjournals.com/oncotarget
of PARP (antibody from Santa Cruz Biotechnology, 
Santa Cruz, CA). HRP-conjugated secondary anti-
rabbit antibodies were purchased from Santa Cruz 
Biotechnology. ECL detection reagent was from Perkin 
Elmer (Shelton, CT).
northern blotting and hybridization
Total RNA (10 µg) from HeLa, HT1080, or HCT116 
cells was analyzed by Northern blot hybridization with 
probes  specific  to  the  Hsp70A1  and  GAPDH  genes. 
The Hsp70A1 probe consisted of a PCR fragment that 
was generated from the Hsp70A1 cDNA (Invitrogen, 
Carlsbad,  CA)  with  primers  specific  for  the  Hsp70A1 
coding sequence (A1s: 5’ CCA CCA TCC CCA CCA 
AGC AGA C3’; A1a: 5’ CAT GAA CCA TCC TCT CCA 
CCT 3’). All other hybridization probes were generated 
by restriction endonuclease digestion from cDNA clones 
(ORIGENE). 
In vivo 35s-protein labeling
HeLa cells were treated with drugs and their 
combinations according to the protocols of experiments. 
The regular culture medium was changed to a methionine/
cysteine-free medium supplemented with 35S-methionine 
and  35S-cysteine (50 µCi/ml) (New England Nuclear/
Perkin Elmer, Shelton, CT) and the cells were incubated 
for an additional 60 min in the presence of drugs. 
Cytoplasmic protein extracts were prepared according to 
the Dignam protocol [53]. Labeled proteins were analyzed 
by electrophoresis in 10% polyacrylamide gels followed 
by autoradiography. 
cell viability assay
A cell viability assay was used to determine the 
cytotoxicity of drugs and drug combinations. Cells were 
grown to 75-80% confluency and then treated for 16 h 
with various combinations and doses of bortezomib and 
puromycin, or hyperthermia (430C for 1h) and bortezomib. 
Cells were collected by trypsinization and a 1:50 dilution 
was seeded in fresh medium without any drugs in a 12-
well plate. Cell viability was determined 72 h later by 
methylene blue staining after fixation of the cells with 
10% formaldehyde. Methylene blue was extracted by 
0.1 M HCl and its absorbance was measured at 560 nm. 
All assays were done in duplicate and the graphs show 
the average data. Trypan blue assay was used to estimate 
MPC11 MM cell viability [54].
In vivo assay for general toxicity of drug 
treatments
To evaluate general toxicity, 5 groups of 8 week old 
BALB/c mice (3 mice/group) were given drug injections 
(intraperitonealy) every two days (5 total injections). 
Group 1 was injected with 1 mg/kg bortezomib; group 2 
received 5 mg/kg puromycin; group 3 received 0.5 mg/
kg bortezomib; group 4 received 0.5 mg/kg bortezomib + 
5 mg/kg puromycin; and group 5 was injected with PBS. 
Individual mouse body weights were determined daily 
and used to calculate the average weight for each group.
In vivo assay for tumor growth in mice
MPC11 cells were washed and resuspended in 
sterile PBS. Cells were injected sub-cutaneous into two 
sites of the shaved abdominal area of BALB/c mice 
(2x105 cells in a single injection). Tumors were measured 
in two dimensions using digital calipers and tumor 
volume was calculated as: tumor volume (mm3) = 0.5 
tumor length x (tumor width)2. On day 8 post-injection, 
tumors were typically ~50 mm3 in size. Tumor-bearing 
mice were divided into four groups of five animals each 
and were given intraperitonealy drug injections every 
2-3 days beginning on day 9. The control group (Group 
1) received PBS injections. Group 2 was injected with 
5 mg/kg puromycin in PBS. Group 3 received 0.5 mg/
kg bortezomib in PBS. Group 4 was injected with a 
combination of the indicated doses of bortezomib and 
puromycin. Tumors were measured every 2 days after the 
first drug injection. Animals were euthanized if tumors 
grew to > 1200 mm3.
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